Skip To Main Content
Danielle A. Baribeau on Muck Rack

Danielle A. Baribeau

As seen in: Nature, Wiley Online Library, Medscape, EClinicalMedicine, Biological Psychiatry
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Danielle A.

Contact Danielle A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Characterizing ARID1B -related disorders and variants of uncertain significance using DNA methylation

|
By Anthony Chen, Manav Jain, Danielle A. Baribeau, William Gibson, Fowzan S. Alkuraya, Juan Dario Ortigoza-Escobar, Graeme R Nimmo, Stephen Scherer, Sanaa Choufani, Sarah Goodman, Rosanna Weksberg, Matthew A. Deardorff
| Nature Verified
Abstract Sequence variants in ARID1B, a subunit of the BRG1 (BRM)-associated factors (BAF) complex, are often challenging to classify clinically due to the broad phenotypic spectrum of ARID1B-related disorders (ARID1B-RD). Our previous work has shown that pathogenic variants in epigenetic regulatory genes are associated with DNA methylation (DNAm) signatures, which have proven diagnostic utility for variant classification.
Open in Who Shared Issue with article?

192. Symptom Cluster Trajectories of Response to Dorsolateral Prefrontal rTMS in Depression: A Three-D Study

|
By Tyler S Kaster, Jonathan Downar, Danielle A. Baribeau, Kevin Thorpe
| Biological Psychiatry Verified
Using the Hamilton Depression Rating Scale (HDRS) sum score to quantify the efficacy of repetitive transcranial magnetic stimulation (rTMS) in treatment-resistant depression (TRD) may overlook the heterogeneity of distinct longitudinal symptom cluster response trajectories to rTMS amongst those with MDD. Identifying these symptom cluster response trajectories could allow for personalized treatment protocols with rTMS.
Open in Who Shared Issue with article?

343. Fasoracetam for Neuropsychiatric Symptoms in Children and Adolescents With 22q11.2 Deletion Syndrome: A Randomized Crossover Phase II Clinical Trial

|
By Danielle A. Baribeau, Sarah Hopkins, Raquel E. Gur, Madeleine Chadehumbe
| Biological Psychiatry Verified
1Holland Bloorview Kids Rehabilitation Hospital 2Perelman School of Medicine of the University of Pennsylvania 3Children's Hospital of Philadelphia, University of Pennsylvania 4Children's Hospital of Philadelphia, Penn Medicine, University of Pennsylvania 5Children's Hospital of Philadelphia 6University of Washington 7Seattle Children’s Research Institute, Seattle Children’s Hospital 8The Hospital for Sick Children, Toronto 9Children's Hospital Colorado 10The Hospital for Sick Children...
Open in Who Shared Issue with article?
See all 8 articles